Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Appili Therapeutics has received the final court approval for its acquisition by Aditxt, Inc., marking a significant milestone in the transaction process. This move will eventually lead to Appili’s delisting from the Toronto Stock Exchange. The transaction is expected to close by the end of 2024, subject to remaining conditions.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue